Tuberc Respir Dis.  2004 Jun;56(6):664-669. 10.4046/trd.2004.56.6.664.

A Case of Primary Pulmonary Plasmacytoma Presenting as Endobronchial Mass

• Suh SY
• Ko GJ
• Kim CH
• Kim YH
• Lee SY
• Lee SY
• Kim JH
• Shin C
• Shim JJ
• In KH
• Kang KH
• Yoo SH

• KMID: 1970473
• DOI: http://doi.org/10.4046/trd.2004.56.6.664

Abstract

Extramedullary plasmacytoma(EMP) comprises 5% of all plasma cell neoplasms and commonly occurs in the upper airway or digestive tract. However, it rarely develops in the lungs. We present a case of primary pulmonary plasmacyotma in a 45 year old man, who presented as an endobronchial mass with a pleural effusion, but without evidence of multiple myeloma. The treatment options for EMP include surgery, surgery and radiotherapy, surgery and chemotherapy or chemotherapy alone. Surgery and radiation therapy appeared to be equally effective forms of treatment. The local recurrence rate was reported to be 30%, with 48% progressing to multiple myeloma, and median survival was reported to be 63-101 months. Our patient was initially treated with melphalan and prednisolone. However the disease progressed, and radiotherapy was combined with chemotherapy. In addition, the chemotherapy regimen was also changed to thalidomide and dexamethasone. The patient did not respond to this treatment regimen and finally died.

Keyword

pulmonary plasmacytoma; extramedullary plasmacytoma; endobronchial mass

MeSH Terms

Dexamethasone
Drug Therapy
Gastrointestinal Tract
Humans
Lung
Melphalan
Middle Aged
Multiple Myeloma
Neoplasms, Plasma Cell
Plasmacytoma*
Pleural Effusion
Prednisolone
Radiotherapy
Recurrence
Thalidomide
Dexamethasone
Melphalan
Prednisolone
Thalidomide